Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report

Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report

Renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusions is a rare subtype of renal tumor. This entity predominantly occurs in juveniles, but rarely in adults. Xp11.2 translocation RCC (tRCC) patients with lymph node or organ metastasis are associated with poor prognosis, an...

Full description

Bibliographic Details
Main Authors: Juping Zhao, Kun Dai, Jialing Xie, Chen Fang, Na Chen, Jun Dai, Danfeng Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
immunotherapy
PD-1
tyrosine kinase inhibitor
Xp11.2 translocation renal cell carcinoma
PTPRD-mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.927299/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.927299/full

Similar Items